Edition:
India

MediciNova Inc (MNOV.OQ)

MNOV.OQ on NASDAQ Stock Exchange Global Market

8.81USD
13 Jul 2018
Change (% chg)

$0.27 (+3.16%)
Prev Close
$8.54
Open
$8.54
Day's High
$8.87
Day's Low
$8.54
Volume
15,518
Avg. Vol
59,800
52-wk High
$14.50
52-wk Low
$4.40

Latest Key Developments (Source: Significant Developments)

MediciNova to collaborate with UCLA researchers in grant-funded clinical trial of MN-166 (ibudilast) in alcohol use disorder and withdrawal
Tuesday, 8 May 2018 

May 8(Reuters) - MediciNova Inc :Says it plans to initiate a clinical trial of MN-166 (ibudilast) in alcohol dependence and withdrawal in collaboration with researchers at the University of California, Los Angeles (UCLA).  Full Article

MediciNova Posts Results Of Phase 2 Clinical Trial Of MN-166 In Methamphetamine Dependence
Thursday, 29 Mar 2018 

March 29 (Reuters) - MediciNova Inc ::MEDICINOVA ANNOUNCES RESULTS OF PHASE 2 CLINICAL TRIAL OF MN-166 (IBUDILAST) IN METHAMPHETAMINE DEPENDENCE.MEDICINOVA INC - ‍DID NOT MEET PRIMARY ENDPOINT OF METHAMPHETAMINE ABSTINENCE CONFIRMED VIA URINE DRUG SCREENS DURING FINAL TWO WEEKS OF TREATMENT​.MEDICINOVA INC - ‍MN-166 (IBUDILAST) DEMONSTRATED A FAVORABLE SAFETY AND TOLERABILITY PROFILE​.MEDICINOVA INC - ‍THERE WAS NOT AN INCREASED RATE OF SERIOUS OR SEVERE ADVERSE EVENTS IN MN-166 (IBUDILAST) GROUP COMPARED TO PLACEBO GROUP​.MEDICINOVA INC SAYS THERE WERE NO INFECTIONS, NO CANCERS, NO CARDIOVASCULAR EVENTS NO DEATHS RELATED TO MN-166.MEDICINOVA - COMMON TREATMENT-RELATED ADVERSE EVENTS DURING STUDY WERE GASTROINTESTINAL ADVERSE EVENTS, OCCURRED WITH HIGHER FREQUENCY IN MN-166 GROUP​.  Full Article

Medicinova Announces Positive Top-Line Results From Clinical Trial Of MN-166 (ibudilast) In ALS
Friday, 8 Dec 2017 

Dec 7 (Reuters) - Medicinova Inc ::MEDICINOVA ANNOUNCES POSITIVE TOP-LINE RESULTS FROM THE CLINICAL TRIAL OF MN-166 (IBUDILAST) IN ALS.MEDICINOVA INC - TRIAL ACHIEVED PRIMARY ENDPOINT OF SAFETY AND TOLERABILITY, AND ALSO DEMONSTRATED EFFICACY TRENDS IN FAVOR OF MN-166.MEDICINOVA INC - THERE WERE 7 SERIOUS ADVERSE EVENTS (SAES) REPORTED DURING STUDY BUT NONE OF SAES WERE RELATED TO STUDY DRUG.MEDICINOVA INC - MN-166 DEMONSTRATED A FAVORABLE SAFETY AND TOLERABILITY PROFILE. ALL SUBJECTS IN STUDY RECEIVED 100 MG OF RILUZOLE PER DAY.MEDICINOVA INC - ALL TREATMENT-RELATED ADVERSE EVENTS (TRAES) WERE MILD TO MODERATE IN INTENSITY & NO SEVERE OR LIFE-THREATENING TRAES WERE REPORTED.  Full Article

Medicinova announces positive top-line results from the Sprint-MS Phase 2B trial of MN-166 (ibudilast)
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Medicinova Inc ::Medicinova announces positive top-line results from the Sprint-MS phase 2B trial of MN-166 (ibudilast) in progressive MS: achieved both primary endpoints including a significant reduction in whole brain atrophy and safety and tolerability.Medicinova Inc - ‍MN-166 demonstrated a statistically significant reduction in rate of progression of whole brain atrophy compared to placebo in study​.Medicinova Inc - ‍MN-166 was safe and well tolerated in study​.  Full Article

MediciNova sees loss per share for year ending Dec 31 of $0.31
Wednesday, 27 Jul 2016 

MediciNova Inc : Says expected loss per share for year ending December 31, 2016 is $0.31 .FY 2016 earnings per share view $-0.31 -- Thomson Reuters I/B/E/S.  Full Article

MediciNova receives notice of allowance for new patent covering MN-001 and MN-002 for the treatment of fibrosis
Tuesday, 26 Jul 2016 

MediciNova Inc :Says it received a notice of allowance from the U.S. Patent And Trademark Office (Uspto) for a pending patent application which covers Mn-001 (Tipelukast) and Mn-002 (A Major Metabolite Of Mn-001) for the treatment of “Fibrosis” which includes a broad range of fibrosis / fibrotic disease in different organs due to different causes.  Full Article

BRIEF-MediciNova to collaborate with UCLA researchers in grant-funded clinical trial of MN-166 (ibudilast) in alcohol use disorder and withdrawal

* Says it plans to initiate a clinical trial of MN-166 (ibudilast) in alcohol dependence and withdrawal in collaboration with researchers at the University of California, Los Angeles (UCLA)